DELAWARE GROUP EQUITY FUNDS V INC
NSAR-A, EX-27.SCCI, 2000-07-31
Previous: DELAWARE GROUP EQUITY FUNDS V INC, NSAR-A, EX-27.SCCC, 2000-07-31
Next: BIOJECT MEDICAL TECHNOLOGIES INC, DEF 14A, 2000-07-31



<TABLE> <S> <C>

<ARTICLE> 6
<CIK> 0000809821
<NAME> DELAWARE GROUP EQUITY FUNDS V
<SERIES>
   <NUMBER> 044
   <NAME> DELAWARE SMALL-CAP CONTRARIAN FUND INSTITUTIONAL
CLASS

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          NOV-30-1999
<PERIOD-END>                               MAY-31-2000
<INVESTMENTS-AT-COST>                        2,051,744
<INVESTMENTS-AT-VALUE>                       2,212,099
<RECEIVABLES>                                  116,852
<ASSETS-OTHER>                                       0
<OTHER-ITEMS-ASSETS>                                 0
<TOTAL-ASSETS>                               2,334,951
<PAYABLE-FOR-SECURITIES>                        65,565
<SENIOR-LONG-TERM-DEBT>                              0
<OTHER-ITEMS-LIABILITIES>                       24,710
<TOTAL-LIABILITIES>                             90,275
<SENIOR-EQUITY>                                      0
<PAID-IN-CAPITAL-COMMON>                     2,169,199
<SHARES-COMMON-STOCK>                          255,556
<SHARES-COMMON-PRIOR>                          235,295
<ACCUMULATED-NII-CURRENT>                       13,825
<OVERDISTRIBUTION-NII>                               0
<ACCUMULATED-NET-GAINS>                      (104,703)
<OVERDISTRIBUTION-GAINS>                             0
<ACCUM-APPREC-OR-DEPREC>                       166,355
<NET-ASSETS>                                 2,244,667
<DIVIDEND-INCOME>                               22,973
<INTEREST-INCOME>                                5,442
<OTHER-INCOME>                                       0
<EXPENSES-NET>                                   8,127
<NET-INVESTMENT-INCOME>                         20,288
<REALIZED-GAINS-CURRENT>                     (104,642)
<APPREC-INCREASE-CURRENT>                      228,083
<NET-CHANGE-FROM-OPS>                          143,729
<EQUALIZATION>                                       0
<DISTRIBUTIONS-OF-INCOME>                       31,765
<DISTRIBUTIONS-OF-GAINS>                       137,412
<DISTRIBUTIONS-OTHER>                                0
<NUMBER-OF-SHARES-SOLD>                              0
<NUMBER-OF-SHARES-REDEEMED>                          0
<SHARES-REINVESTED>                                  0
<NET-CHANGE-IN-ASSETS>                         143,733
<ACCUMULATED-NII-PRIOR>                         25,302
<ACCUMULATED-GAINS-PRIOR>                      137,532
<OVERDISTRIB-NII-PRIOR>                              0
<OVERDIST-NET-GAINS-PRIOR>                           0
<GROSS-ADVISORY-FEES>                            7,918
<INTEREST-EXPENSE>                                   0
<GROSS-EXPENSE>                                 22,838
<AVERAGE-NET-ASSETS>                         2,167,999
<PER-SHARE-NAV-BEGIN>                            8.930
<PER-SHARE-NII>                                  0.128
<PER-SHARE-GAIN-APPREC>                          0.441
<PER-SHARE-DIVIDEND>                           (0.135)
<PER-SHARE-DISTRIBUTIONS>                      (0.584)
<RETURNS-OF-CAPITAL>                             0.000
<PER-SHARE-NAV-END>                              8.780
<EXPENSE-RATIO>                                  0.750


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission